Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3648-3656, July 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yabkowitz, R.
Right arrow Articles by Dixit, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yabkowitz, R.
Right arrow Articles by Dixit, V. M.

Human Carcinoma Cells Bind Thrombosphondin through a Mr 80,000/105,000 Receptor1

Rachel Yabkowitz and Vishva M. Dixit2

Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan 48109

The metastatic 11B squamous carcinoma cell line synthesizes and secretes high levels of the extracellular matrix glycoprotein thrombospondin (TSP) and displays aggressive invasiveness in a nude mouse model forming highly undifferentiated tumors. The importance of adhesion events involving extracellular matrix proteins and the tumorigenic cell surface in metastasis led us to investigate the nature of the 11B cell surface receptor for TSP. Using TSP affinity chromatography, a cell surface complex of molecular weight 80,000 and 105,000 was isolated that appears to function as a receptor for TSP. Binding was specific for the COOH-terminal Mr 140,000 fragment of TSP. TSP and the Mr 140,000 fragment competed for the binding of the 125I-labeled Mr80,000/105,000 cell surface complex to TSP-coated microtiter wells in a dose-dependent manner with half-maximal inhibition observed at 16 and 40 µg/ml, respectively. In contrast, the NH2-terminal heparin-binding domain did not inhibit binding in a dose-dependent manner. Other extracellular matrix proteins, such as laminin, vitronectin, or type I collagen, were also unable to inhibit the binding of the 125I-labeled Mr 80,000/105,000 cell surface complex to TSP. The specificity of the Mr 80,000/105,000 receptor for the Mr 140,000 fragment of TSP was further confirmed through the use of monoclonal antibodies. Monoclonal antibody C6.7 specific for the distal COOH terminus of TSP, but not monoclonal antibody A2.5 specific for the heparin-binding domain, inhibited binding. Binding was observed to be strongly Ca2+ dependent, slightly Mg2+ dependent, and independent of Mn2+. Immunoprecipitation analyses demonstrated no apparent cross-reactivity between the Mr 80,000/105,000 TSP receptor and members of the ß1 or ß3 integrin receptor families. Additionally, V-8 protease mapping demonstrated that the Mr 80,000 and 105,000 polypeptide bands are not related to each other through proteolytic processing. This initial identification and characterization of a carcinoma cell TSP receptor should allow a more detailed examination of the role of TSP in metastatic adhesion and motility.

1 This work was supported by NIH Grant CA 51888.

2 To whom requests for reprints should be addressed, at Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Box 0602, Ann Arbor, MI 48109-0602.

Received 2/18/91. Accepted 5/ 1/91.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Tanaka, H. Sonoo, J. Kurebayashi, T. Nomura, S. Ohkubo, Y. Yamamoto, and S. Yamamoto
Inhibition of Infiltration and Angiogenesis by Thrombospondin-1 in Papillary Thyroid Carcinoma
Clin. Cancer Res., May 1, 2002; 8(5): 1125 - 1131.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Feitsma, H. Hausser, H. Robenek, H. Kresse, and P. Vischer
Interaction of Thrombospondin-1 and Heparan Sulfate from Endothelial Cells. STRUCTURAL REQUIREMENTS OF HEPARAN SULFATE
J. Biol. Chem., March 24, 2000; 275(13): 9396 - 9402.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
D. W. Dawson, S. F. A. Pearce, R. Zhong, R. L. Silverstein, W. A. Frazier, and N. P. Bouck
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
J. Cell Biol., August 11, 1997; 138(3): 707 - 717.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Chen, D. K. Strickland, and D. F. Mosher
Metabolism of Thrombospondin 2. BINDING AND DEGRADATION BY 3T3 CELLS AND GLYCOSAMINOGLYCAN-VARIANT CHINESE HAMSTER OVARY CELLS
J. Biol. Chem., July 5, 1996; 271(27): 15993 - 15999.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. W. Tsao and S. A. Mousa
Thrombospondin Mediates Calcium Mobilization in Fibroblasts via Its Arg-Gly-Asp and Carboxyl-terminal Domains
J. Biol. Chem., October 6, 1995; 270(40): 23747 - 23753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.